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A b s t r a c t  
The aim of the present study is to evaluate the gum, Dikamali, as a tablet binder employing 
zidovudine as a model drug. Zidovudine tablets were prepared by wet granulation technique using 
Dikamali as a tablet binder. The Dikamali was used in wet form and dry form. Granules were 
evaluated for pre-compression parameters:  tapped density, bulk density, compressibility index, 
hausner ratio, and angle of repose. All the parameters were found to be within the acceptable limits. 
The tablets were evaluated for hardness, friability, weight variation, disintegration, content 
uniformity, and dissolution.  
For the formulations F1-F3D; F1-F3W; F4-F7 (see Table 1) the parameters of friability, disintegration 
time, and hardness were measured and their values range from 0.57-0.73% (w/w), 0.83-0.97% 
(w/w), 0.69-0.99% (w/w); 12-13 min, 10-12 min, 10-12 min; and 5-6.9 kg/cm2, 4.5-5.1 kg/cm2, 4.1-
5.2 kg/cm2; respectively. The binding efficacy of Dikamali was compared with the standard binders, 
starch mucilage and polyvinyl pyrrolidone, using dissolution studies. The binders, Dikamali and 
starch, were compared at similar concentrations [2.5% (w/v), 5% (w/v), and 7.5% (w/v)], and the 
finalized formulation (F1D) was compared with a 10% (w/v) concentration of starch mucilage and a 
10% (w/v) concentration of polyvinyl pyrrolidone (PVP). Dikamali [2.5% (w/v)] in dry form (i.e. F1D) 
showed the same percent drug release as that of the 10% (w/v) of starch mucilage and of polyvinyl 
pyrrolidone. In conclusion, Dikamali could well be used as a binding agent in the formulation of 
tablet dosage forms, and Dikamali is more effective in dry form than the wet form. 
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Introduction 
Now-a-days, there is an increasing importance to natural polymers 
for their use especially as natural binders, emulsion stabilizers, 
suspending agents, thickeners [1], sustain-release polymers, 
disintegrants [2], and potential carriers in site specific delivery [3]. 
Natural gums are economical, easily available, and useful as tablet 
binders. The growing significance to natural polymers is due to 
their advantages, such as biodegradability, biocompatibility, non-
toxicity, local availability, better patient tolerance, as well as public 
acceptance [4].  In addition, most of the gums are obtained from 
edible sources. Globally available natural polymers are from 
different origins including land plants (potato starch [5], gum ghatti, 
gum karaya, gum tragacanth [6], gum Dikamali) land animals 
(chitin and chitosan, chondroitin sulfate), marine plants and 
animals (agar, carrageenans, alginic acid), and microbials (xanthan 
gum, dextran, bakerÊs yeast glycan) [7].  
We chose to use Dikamali in this study. To the best of our 
knowledge, no significant work has been reported on Dikamali as a 
tablet binder. Dikamali is one such natural gum of the shrub 
Gardenia gummifera belonging to the family Rubiaceae [8, 9]. It is 
a transparent greenish yellow color with a sharp pungent taste and 
peculiar odor [10]. It is an oleogum resin, containing mostly 
polysaccharides, flavonoids, alkaloids, and proteins in small 
quantities. Commercial samples of Dikamali contain resins 
(89.9%), volatile oils (0.1%), and plant impurities (10%).  Dikamali 
is commonly known by many names:  pindava in Sanskrit; nadi-
Hingu in Hindi; manchi bikki and tella manga in Telugu; kamarri in 
Gujarati; kambilippicin in Tamil; Dikamali in Bengal and Marati; and 
cittu-bikke and dikkemalli in Kannada [8]. 
Dikamali is soluble in different solvents like water, HCl (0.1N), 
NaOH solutions, and phosphate buffer at pH 7.4. [11]. Medicinal 
properties of Dikamali include anti-spasmodic, expectorant, 
carminative, diaphoretic, and anthelmintic property [12]. Physical 
and chemical properties of Dikamali include a melting point at 45-
50ÀC, an acid value of 87.1, an iodine value of 80.8; and a 
saponification value of 172.3 [13]. It shows turbid precipitation with 
acetone, alcohol, and ether. Others have reported that the 
structure of Dikamali contains six new cycloartane triterpenes (i.e. 
Dikamaliartanes A-F), along with a known flavonoid, using NMR 
spectroscopy. All six cycloartanes are characterized by an open A-
ring with a free COOH group at 3-C. In four of them, the C-atoms, 
C (23)-C (27), form a 4-methylfuran-2-yl moiety [14]. Preliminary 
phytochemical investigation of Dikamali demonstrates that 
Dikamali shows positive results for MolischÊs test, FehlingÊs test, 
BenedictÊs test, the tannic acid test, a test for flavonoids, and a test 
for gums and a negative result for BarfordÊs test. From these data 
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one can conclude that Dikamali is a composite of flavonoids and 
carbohydrates, specifically polysaccharides.  
Zidovudine (AZT) is the drug of choice for AIDS treatment [15]. 
Zidovudine is a nucleoside reverse transcriptase inhibitor (NRTI), 
which shows action against Human Immunodeficiency Virus Type 
1 (HIV-1) by converting into its active form, zidovudine triphosphate 
[16].  ZidovudineÊs half life is 4 hours and shows protein binding of 
30-38%. It is a white or brownish powder, which is soluble in 
ethanol (67 mg/ml), water (25 mg/ml), 0.1N HCl (28 mg/ml), and 
phosphate buffer at pH 6.8 (20.1 mg/ml.) [17]. Rapid and nearly 
complete absorption of zidovudine from the gastrointestinal tract 
follows oral administration; however, because of first-pass 
metabolism, systemic bioavailability of zidovudine is approximately 
65% (i.e., 52-75%). After intravenous dosing, about 29% of the 
dose, that was excreted in the urine, was unchanged, and about 
45% of the dose was excreted as GZDV (glucouronide form of 
zidovudine) [18]. 
This manuscript mainly discusses the use of Dikamali as a simple 
binder as well as its future scope to use it as a sustain-release 
polymer. Dikamali has been established as a tablet binder by 
performing dissolution studies. Dikamali was used as a solution 
and dry powder, and the dry powder showed a greater potential as 
a tablet binder. 
Materials and Methods 
Materials 
Zidovudine was received as a gift sample from Hetero Drugs 
Private Limited (Hyderabad, India). Dikamali was received as a gift 
sample from Girijen Co-operative Corporation (Vishakhapatnam, 
India). All the other chemicals used for study were purchased from 
Finar Chemicals. 
Methods 
Tablet Preparation 
Different zidovudine formulations containing Dikamali as a binder 
were prepared by wet granulation technique. Formulations (F1 to 
F7) were developed as shown in Table 1.  Zidovudine and other 
excipients were weighed accurately and mixed with distilled water 
to prepare samples of uniform mass. Each prepared mass was 
passed through #16 mesh, and the resultant granules were dried in 
a hot air oven at 60ÀC for 20 min. The dried granules were passed 
through #22 mesh and then treated with magnesium stearate and 
talc. Dried granules were subjected to suitable compression using 
tablet compression machine (Rimek). In the wet granulation 
technique, binder was used in dry form as well as wet form. In dry 
form Dikamali was used as a powder, and in wet form Dikamali 
was used as a solution by dissolving in distilled water [19, 20]. 
 
 
 
 
Table 1: Formulation series: 
Gives an idea about how the different formulations were designed. 
 
F1, F2, and F3 are the formulations containing Dikamali as a 
binder. ÂDÊ denotes the Dikamali in dry form; ÂWÊ denotes the 
Dikamali in wet form. F4-F7 are the formulations containing starch 
paste as a binder 
Physical characterization of granules 
FTIR studies were carried out to identify any possible chemical 
interaction between zidovudine and Dikamali. IR spectrums of 
Zidovudine, Dikamali, and their physical mixture were recorded 
using KBr pellets. The spectra were scanned over a wavenumber 
range of 4200 to 500 cmă1 [21]. The granules were also tested for 
angle of repose [22], bulk density, tapped density, compressibility 
index, and HausnerÊs ratio according to standard procedures [23]. 
Evaluation of tablets 
The prepared matrix tablets were evaluated for weight variation, 
hardness, friability, disintegration, and content uniformity using 
reported procedures. Weight variation was evaluated on 20 tablets 
using an electronic balance, and the test was performed according 
to a commonly used method. Friability was determined by taking 
10 tablets in a Roche friabilator for 4 min at 25 rpm. Tablet 
hardness was determined for 6 tablets using a Monsanto hardness 
tester. The drug content of the manufactured tablets of each batch 
was determined in triplicate. For each batch 20 tablets were taken, 
weighed, and finely powdered. An accurately weighed quantity of 
powder was taken and analyzed after making appropriate dilutions 
with water [24, 25]. 
In vitro drug release study 
The in vitro release of zidovudine from formulated tablets was 
carried out for 60 minutes in phosphate buffer at pH 7.4. The 
studies were performed in a USP Dissolution Apparatus II (Paddle 
type) at 37 μ 0.5ĈC and 50 rpm speed. Samples were taken at 5, 
10, 15, 30, 45, and 60 minutes intervals, diluted to suitable 
concentration, and analyzed for zidovudine content at 267 nm by 
using UVăvisible spectrophotometer [26]. 
Results and Discussion 
In the present study different concentrations of binders:  Dikamali 
(D) and starch (S) [2.5% w/v D, 5% w/v D, 7.5% w/v D, 2.5% w/v S, 
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5% w/v S, 7.5% w/v S, and 10% w/v S] were used. Tablets of 
zidovudine were prepared using Dikamali as a binder both in wet 
form and dry form using wet granulation technique, shown in Table 
1. A total of ten different formulations were prepared, in which 6 
formulations have Dikamali (F1 to F3 D, W) and 4 formulations 
have starch paste (F4 to F7) as a binder. UV-Visible spectra 
showed characteristic λmax of zidovudine at 257nm. FTIR spectra 
of zidovudine (Fig. 1), Dikamali (Fig. 2), and their physical mixture 
(Figure. 3), were taken. The comparison of all the three spectra 
was shown in Figure. 4. All the characteristic peaks of pure drug, 
such as, C-N amine stretching (1030-1250cm-1), N-H stretching 
(3200-3500 cm-1), C=O stretching (1600-1700cm-1), and O-H 
stretching (3100-3400cm-1) were observed in the spectrum of drug 
zidovudine and Dikamali mixture indicates that there was no 
interaction between the drug and polymer.  
 
 
Figure. 1: FTIR Spectra of Zidovudine showing different stretching 
vibrations of pure drug  
 
 
Figure. 2: FTIR Spectra of Dikamali showing absorption bands of 
different functional groups as generally shown by natural gums. 
 
Figure. 3: FTIR Spectra of Zidovudine-Dikamali Mixture 
 
 
 
 
 
 
 
 
 
Figure. 4: Comparison FTIR Spectra of Zidovudine (Blue), 
Zidovudine+Dikamali (Red), Dikamali 
 
 
The prepared granules were tested for flow properties:  angle of 
repose, bulk density, tapped density, compressibility index, and 
HausnerÊs ratio. Even though all the formulations showed results 
within limits, the formulations containing dry Dikamali (F1 to F3 D) 
showed accurate results compared to formulations containing 
Dikamali solution (F1 to F3 W). The results were shown in Table 1 
and Table 3. The compressed tablets were evaluated for hardness, 
friability, weight variation, disintegration, and content uniformity. 
Tablets with dry Dikamali (F1 to F3 D) were harder, more friable, 
and displayed less disintegration time than tablets containing 
Dikamali solution (F1 to F3 W). The results were shown in Table 2 
and Table 4. 
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Table 2: Characterization of Granules 
The results of different evaluation parameters done on granules 
those were prepared using binder in dry form. 
 
Values μ S.D.; n=3 
 
Table 3: Evaluation of Tablets  
Different evaluation parameters done on tablets those were 
prepared using binder in dry form. 
 
 
Values μ S.D.; n=3 
 
Table 4: Characterization of Granules  
Different evaluation parameters done on granules those were 
prepared using binder in wet form. 
 
 
Values μ S.D.; n=3 
 
 
Table 5: Evaluation of Tablets  
Different evaluation parameters done on tablets those were 
prepared using binder in wet form. 
 Values μ S.D.; n=3 
 
Dissolution studies were performed on ten different formulations. 
Comparing equal concentrations of Dikamali and starch as binders, 
Dikamali formulations showed the better results compared to 
starch (Figure. 5 and Figure.7). Overall, the formulations with 2.5% 
w/v Dikamali (F1D and F1W) were finalized because at the lowest 
possible concentration they showed 95% and 98% drug release in 
60 minutes with correlation coefficients of 0.983 and 0.932 for F1D 
and F1W, respectively. The final formulations were compared with 
two standard binders: starch and polyvinyl pyrrolidone at their 
standard concentration of 10% w/v by using the dissolution 
technique (Figure.6 and Figure.8). It was observed that the F1D 
formulation showed exactly the same result as that of formulations 
containing standard binders; whereas, F1W displayed deviation in 
percent drug release. The reason why F1D showed improved 
results compared to F1W is the Dikamali, in the F1W formulation, 
was initially dissolved in water, and Dikamali solution was used in 
the F1W formulation as a binder. So, in the wet form the pore size 
of Dikamali polymer was increased and passage channels got 
widened which allowed faster release of drug with a poor 
regression coefficient. However, in the F1D formulation there was 
no previous contact of Dikamali with water until the last step of 
preparation. So, F1D showed constant drug release similar to 
standard binders with a good regression coefficient, although, it 
took more time to release 99% of drug than F1W.  A lower 
concentration of Dikamali than standard binders could be used to 
achieve the same level of binding. Drug release from the F2D and 
F3D was very slow because the high concentration of binder 
hindered the drug release by providing a greater hardness and 
compactness to the formulation. This property of binder indicates 
that the Dikamali should be investigated as a sustain release 
polymer. Finally, the formulation containing 2.5% w/v Dikamali in 
dry form (FID) was proven as the best formulation. 
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Figure. 5: Drug release pattern of seven different formulations 
prepared using the Dikamali and  starch mucilage in dry form. 
        
 
Figure.6: Comparison of F1 D (optimized formulation) drug release 
pattern with Standard binders:  starch mucilage and PVP. 
 
Figure. 7: Drug release pattern of seven different formulations 
prepared using the gum Dikamali and starch mucilage in wet form. 
 
 
Figure.8: Comparison of F1W drug release pattern with Standard 
binders: starch mucilage and PVP. 
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Conclusion 
The current study demonstrates that the tablets of zidovudine can 
be prepared by employing Dikamali alone as a binder. The 
evaluation of tablets has revealed that the binding efficacy of the 
tablets prepared using Dikamali at 2.5% concentration is 
comparable to the efficacy of the tablets prepared using 10% 
starch and 10% PVP as standard binders. Formulations containing 
Dikamali seem to produce more appropriate conventional tablets 
than other polymers at low concentrations. Dikamali be able to use 
as a binder in both dry and wet forms, but Dikamali in dry form is 
better than wet form. Therefore, Dikamali could be used well as a 
binding agent in the formulation of tablet dosage forms. Future 
scope of this project is that Dikamali can be developed as a sustain 
release polymer at higher concentrations. 
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